Endometrial cancer is the most common pelvic gynaecological malignancy in industrialised countries. Although 75% are treated at an early stage, 15 to 20% recur. There is a need for more effective systemic therapies, as no new targeted therapies are yet available in standard clinical care, and response to conventional systemic therapy is limited ([@bib3]). Several prognostic markers exist, and recent studies have indicated promising new targets to develop novel strategies for systemic therapies in endometrial cancer ([@bib30]). Still, no markers are available to predict response to such therapy.

Traditionally, endometrial cancer has been divided into two subgroups, type I and type II carcinomas, to assess the risk of recurrent disease. Type I endometrial carcinoma is associated with good prognosis, low grade, endometrioid morphology and rarely metastasise to regional and distant sites ([@bib9]). Type II endometrial carcinoma is associated with poor prognosis, non-endometrioid histology and high grade. Still, there is considerable overlap, and as tool to predict prognosis this classification may be improved, as 20% of type I cancers recur and 50% of type II cancers do not. Although the molecular alterations reported for type I and type II cancers are overlapping, type I cancers are significantly more often *Homo sapiens* v-Ki-ras2 Kirsten rat sarcoma viral oncogene (*KRAS)* and *PTEN* mutated, microsatellite instable, diploid and expressing oestrogen- and progesterone receptors (ER, PR) ([@bib17]). Type II cancers, in contrast are more often aneuploid and with altered expression of p53, p16 and with hormone receptor loss. These differences are of prognostic value; nevertheless, the molecular characteristics distinguishing Type I and Type II cancers have so far had limited impact for tailoring systemic therapies.

*Homo sapiens* v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue is a small GTPase and a member of the RAS superfamily of proteins linked to the carcinogenic process in preclinical models. Knock-down of *KRAS* in pancreatic cancer cell lines leads to decreased motility and proliferation and a decreased expression of pERK1/2, *SNAIL* and *Nf-kB*, all factors related to epithelial to mesenchymal transition ([@bib28]). In colorectal cancer, *KRAS* has been reported to induce *VEGF* and inhibit apoptosis through *Akt* phosphorylation under hypoxic conditions ([@bib39]).

Activating *KRAS* mutations have been detected in precursor lesions for colorectal and endometrial cancers indicating that these are early events ([@bib4]). Mutations have been found to have a prognostic impact in lung-, pancreatic- and colorectal cancers ([@bib11]; [@bib19]). In endometrial cancer, findings have been inconsistent, with reported different prognostic impact for different age groups ([@bib12]; [@bib33]). Furthermore, *KRAS* mutations have been found to predict lack of response to *EGFR* inhibition in lung- and colorectal cancers ([@bib1]). In endometrial cancer trials of *EGFR* inhibitors have been limited, although some studies reported partial response ([@bib24]; [@bib3]).

Other measures for *KRAS* alterations, although less studied than mutations, have supported a relevance of *KRAS* status for clinical phenotype in cancer ([@bib38]). In lung cancer patients with *KRAS* amplification and *KRAS* mutations, the latter only associated with poor survival, but with no independent prediction of response to therapy ([@bib32]). Lung cancers with *KRAS* amplification have been reported to have increased expression levels of p21 (CDK1), suggesting an impact on cell cycle regulation ([@bib37]). In endometrial cancers, one previous study demonstrated a poor prognostic impact of amplifications of the 12p12.1 region harbouring *KRAS* ([@bib30]). On this background, we have investigated several aspects of *KRAS* alterations including mutation, amplification and mRNA levels in relation to transcriptional alterations and clinical phenotype. To study this, we have applied a unique sample set of freshly frozen primary- and metastatic endometrial carcinoma lesions as primary investigation set for a global and comprehensive characterisation of molecular changes, and an independent, large and extensively annotated patient series for validation of findings. In particular, we wanted to investigate which *KRAS* alterations in endometrial carcinoma that link to aggressive disease.

Materials and Methods
=====================

Patient series
--------------

From May 2001 through 2009, freshly frozen and formalin-fixed paraffin-embedded (FFPE) tissues have been prospectively collected from primary- and metastatic endometrial carcinoma lesions from patients treated at the Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway, after collection of informed consent. In total 461 patients where included for the various analyses in this study. Formalin-fixed paraffin-embedded tumour tissue from hysterectomy specimens from 414 primary tumours and 61 metastatic lesions were mounted in tissue micro arrays (TMA) for amplification studies of KRAS using fluorescence *in situ* hybridisation (FISH). DNA and RNA were extracted from freshly frozen tissue from 264 primary- and 22 metastatic lesions. Two hundred fifteen of these primary tumours and all metastases were included in the FISH series. Extracted DNA was used for SNP array- (74 patients) and mutation analyses (264 patients), RNA were applied for micro-array analysis (122 patients) and 161 patients were used for the qPCR validation series. Primary tumour tissue in TMAs were analysed by immunohistochemistry for ER, PR and p53 protein expressions (461, 461 and 390 patients, respectively). The research has been approved by the Norwegian Data Inspectorate (961478-2), Norwegian Social Sciences Data Services (15501) and the Local ethical committee (REKIII nr. 052.01). Women gave informed consent.

Clinico-pathological data including age at diagnosis, International Federation of Gynaecology and Obstetrics (FIGO) stage according to the 2009 criteria ([@bib8]; [@bib21]), histological subtype and grade, treatment and follow-up information were available for all cases and were investigated in relation to KRAS alterations.

Follow-up data regarding recurrence and survival were collected from patient records and correspondence with physicians responsible for outpatient care. Data were crosschecked with data registered at the Norwegian Cancer Registry and Register for Causes of deaths, Statistics, Norway. Date of last follow-up was April 1st 2010. The median follow-up for survivors was 39 months (range 2--90), 48 (12%) patients died because of endometrial cancer during follow-up.

The therapy consisted of hysterectomy and bilateral salpingo-oophorectomy unless surgery was contraindicated owing to co-morbidity. Pelvic lymphadenectomy as part of surgical staging was conducted after an overall assessment of the patients\' condition by the responsible surgeon as previously reported ([@bib36]). Adjuvant therapy was recommended for patients with FIGO stage ⩾II and high-risk FIGO stage I patients, defined as non-endometrioid tumours or deeply infiltrating endometrioid grade 3 tumours. Of the 461 patients included in our analysis 122 (26.4%) patients were given adjuvant treatment. External radiation was given to 58 (12.6%), internal radiation to 2 (0.4%), chemotherapy to 54 (11.7%), anti-hormonal treatment to 5 (1.1%) and chemotherapy combined with radiation to 3 (0.7%) patients.

Tissue micro-array construction
-------------------------------

Haematoxylin and eosin-stained slides from individual tumour specimens were evaluated to identify the area of highest tumour purity. Tissue cylinders of diameter 0.6 mm were punched out from the selected areas for each corresponding paraffin block and mounted into a recipient block using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA). This method has been described and its usefulness validated in several earlier publications ([@bib15]; [@bib5]). The recipient blocks were treated at 40 °C for 20 min and stored at 4 °C before 5 μm microtome sectioning for FISH analyses. Representative tumour tissue was available in TMAs for FISH from 414 hysterectomy specimens and from 61 corresponding metastatic lesions of these patients.

Immunohistochemistry
--------------------

Tissue micro array sections were dewaxed in xylene and rehydrated in ethanol before microwave antibody retrieval. The sections were incubated for 60 min with p53 antibody (Dako M7001, Copenhagen, Denmark), diluted 1:1000 and for ER and PR as previously reported ([@bib6]; [@bib16]). The staining was recorded as previously described ([@bib31]). In short, a semi-quantitative and subjective grading system was used, and a staining index was calculated as a product of staining intensity (0--3) and area of positive tumour cells (1⩽10%, 2=10--50% and 3⩾50%).

Copy-number assessment
----------------------

For FISH analysis, TMA sections were incubated at 56 °C overnight and treated according to the Paraffin Pre-treatment Protocol (Abbot molecular, Wiesbaden, Germany). Hybridisation was performed according to protocol from Abbot molecular. Briefly the sections were dewaxed in xylene, dehydrated in 100% ethanol, air-dried and treated with proteases for 12 min, denatured and hybridised overnight at 37 °C with *KRAS*/centromere enumeration probe (*KRAS*/CEP12q; Abbot Molecular). Slides were washed with post hybridisation buffer at 72 °C, counterstained with 40,60-diamidino-2-phenylindole (DAPI), mounted, and stored in the dark before signal enumeration. For FISH analysis, the slides were examined by Zeiss fluorescence microscope (Göttingen, Germany) equipped with a × 63 oil immersion objective. Each slide was scanned at low power with a DAPI filter to recognise the TMA map. Areas of optimal tissue digestion and no overlapping nuclei were selected in each core for counting. In each case, signals for probe and control were counted in 40--60 cells. Amplification of *KRAS* was defined as a final ratio obtained for *KRAS*/CEP12q probes ⩾2.0; *KRAS* gain was defined as *KRAS*/CEP12q ratio\>1.0 but \<2.0. Micrographs were taken from each amplified spot, using the Zeiss Axiovision software. Copy-number alterations assessed by SNP array were available for a subset of 74 patients from previous studies, and these data were applied for analysis of *KRAS* copy-number alterations in relation to mRNA expression levels in microarrays.

Oligonucelotide DNA microarray
------------------------------

The RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and hybridised to Agilent Whole Human Genome Microarrays 44 k (Cat. no. G4112F) according to the manufacturers instruction ([www.agilent.com](http://www.agilent.com)), and as previously described ([@bib16]). Microarray data have been deposited in the ArrayExpress Archive database, <http://www.ebi.ac.uk/arrayexpress/> (ArrayExpress accession: E-MTAB-1007). mRNA expression data of KRAS were obtained from DNA-microarrays and a significance analysis of microarray (SAM) was performed to investigate genes significantly differentially expressed (FDR \<0.05) in *KRAS* amplified compared with non-*KRAS-*amplified tumours based on SNP-array data. The subset of patients harbouring KRAS amplifications in FISH analyses with available microarray data was to small to allow meaningful statistical analysis (*n*=3).

PCR and DNA sequencing
----------------------

Genomic DNA was extracted from freshly frozen tissue samples and investigated for point mutations in exon 2 codon 12 and 13 of *KRAS* and exon 9 and 20 of phosphatidylinositol-4,5-bisphosphate 3-kinase *PIK3CA,* primers and conditions listed in [Supplementary Section 1](#sup1){ref-type="supplementary-material"}. cDNA was synthesised from 1 μg RNA by the High capacity RNA to cDNA kit (Applied Biosystems, Foster City, CA, USA). Gene expression of *KRAS* was determined using the TaqMan gene expression assay *KRAS*-Hs00932330_m1 (Applied Biosystems). All samples were run on micro fluidic cards with GAPDH-Hs99999905_m1 as endogenous control according to manufacturers instruction, and as previously described ([@bib16]).

Statistical analysis
--------------------

Statistics were performed using the statistical programme SPSS 18.0 (Quarry Bay, Hong Kong). Associations between categorical variables were evaluated by Pearson\'s *χ*^2^-test. Mann--Whitney *U*-test was used for analysis of continuous variables between categories. *P*-values represent two-sided tests and are considered of statistical significance when *P*\<0.05. Univariate analyses of time to recurrence (recurrence-free survival) and death because of endometrial carcinoma (disease-specific survival) were performed using the Kaplan--Meyer method. Differences in survival were estimated by the Mantel--Cox log-rank test.

In the statistical analysis, cutoff values were based on quartiles, also considering the frequency distribution for each marker, the size of subgroups and number of events in each category. Groups with similar survival were merged.

Results
=======

Amplification of *KRAS* is associated with aggressive disease and metastasis
----------------------------------------------------------------------------

Analysis of *KRAS* copy-number changes by FISH analysis showed a large variation in *KRAS*/CEP12q gene probe ratio from 2 : 2 to \<20 : 2. Defining cases with a ratio ⩾1 and\<2 as gain; and ⩾2 as amplified in the FISH analysis, *KRAS* gain or amplification was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated ([Figure 1A--D](#fig1){ref-type="fig"}). There was no significant difference between gain and amplification of *KRAS* gene copy number in terms of prognosis. Presence of *KRAS* gain or amplification were highly significantly associated with traditional markers for aggressive phenotype including high age, FIGO stage, non-endometrioid histology, high grade, presence of lymph node metastasis, aneuploidy and loss of hormone receptors ([Table 1](#tbl1){ref-type="table"}). Gain or amplification of *KRAS* was also highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (*P*\<0.001) ([Figure 1B](#fig1){ref-type="fig"}). Amplification of *KRAS* maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.2--5.8, *P*=0.02). When adjusting for adjuvant treatment, in addition to these clinico-pathological variables, *KRAS* amplification also maintained its independent prognostic impact in Cox\' multivariate analyses (HR=2.7, 95% CI: 1.2--6.1, *P*=0.014). When comparing primary and metastatic endometrial carcinoma lesions, we find a significant increase in the proportion of samples with *KRAS* gain or amplification from 3% in 414 primary lesions investigated to 18% in 61 metastatic lesions studied (*P*\<0.001) ([Figure 1C](#fig1){ref-type="fig"}). There was no significant correlation between *KRAS* amplification and PIK3CA mutations ([Table 1](#tbl1){ref-type="table"}). However, *KRAS* amplification was highly significantly correlated to pathological p53 expression estimated by immunohistochemistry ([Table 1](#tbl1){ref-type="table"}). In analysis of differentially expressed genes in tumours harbouring *KRAS* amplifications (*n*=10) compared with tumours without *KRAS* amplifications (*n*=64), we find seven genes to be significantly differentially expressed. Two genes were upregulated, whereas five genes were downregulated as listed in Table 4.

High KRAS mRNA level reflects aggressive phenotype
--------------------------------------------------

To further investigate the effect of *KRAS* amplification on mRNA levels, we used mRNA microarrays from 122 primary and 19 metastatic lesions, and a validation cohort analysing mRNA expression of *KRAS* by qPCR in additionally 161 freshly frozen primary endometrial carcinoma lesions. High *KRAS* mRNA expression was significantly associated with high FIGO stage, non-endometrioid histology, high grade, lymph node metastasis, aneuploidy and hormone receptor loss ([Table 2](#tbl2){ref-type="table"}, [Figure 2A and B](#fig2){ref-type="fig"}). The *KRAS* mRNA levels increased significantly from primary to metastatic lesions ([Figure 2C](#fig2){ref-type="fig"}) and in amplified compared to unamplified samples (estimated by SNP array, [Figure 2D](#fig2){ref-type="fig"}). In line with this, high *KRAS* mRNA level was associated with poor prognosis in the validation cohort (*n*=161; [Figure 2E](#fig2){ref-type="fig"}, *P*=0.003), and with a similar trend for the slightly smaller micro-array cohort (*n*=122; *P*=0.08). In Cox multivariate analysis *KRAS* mRNA expression did not maintain its prognostic significance (HR=1.32, 95% CI: 0.9--2.0, *P*=0.17) adjusted for age, histological type, grade and FIGO stage. Presence of mutations in the *PIK3CA* gene was not correlated with increased *KRAS* mRNA expression ([Table 2](#tbl2){ref-type="table"}). High *KRAS* mRNA expression was significantly correlated to pathological p53 expression by immunohistochemistry ([Table 2](#tbl2){ref-type="table"}).

Mutations of *KRAS*
-------------------

As *KRAS* mutations have been linked to response to targeted therapy in other cancer types, and its relation to prognosis in endometrial cancer is unsettled, we further investigated primary and metastatic lesions for presence of *KRAS* mutations in DNA extracted from freshly frozen 264 primary- and 22 metastatic lesions. We found that 14.7% of primary tumours harboured mutations in exon 2 of the *KRAS* gene. Mutations of *KRAS* were significantly more often present in grade 1 and 2 tumours, the endometrioid subtype and among obese patients, but no other significant associations were seen between mutational status for *KRAS* and any of the other variables investigated ([Table 3](#tbl3){ref-type="table"}). In line with this, *KRAS* mutations did not influence prognosis (*P*=0.67) ([Figure 3A](#fig3){ref-type="fig"}). When comparing primary to metastatic endometrial carcinoma lesions, we find no increase in the proportion of samples with *KRAS* mutations. Contrasting the findings for *KRAS* amplifications, patients with *KRAS* mutations have lower *KRAS* mRNA expression than patients without *KRAS* mutations in exon 2 (*P*=0.035) ([Figure 3B](#fig3){ref-type="fig"}). Although not significantly anti-correlated, only one of the 39 *KRAS*-mutated samples was *KRAS* amplified. Interestingly, we find that only 3 of 36 patients harbouring PIK3CA mutations had overlapping KRAS mutations ([Table 3](#tbl3){ref-type="table"}). Mutation of KRAS was not correlated to p53 expression.[](#tbl4){ref-type="table"}

Discussion
==========

Alterations of *KRAS* are considered to be an important biological factor in several cancer types ([@bib27]). Over the last decade, the main focus has been on *KRAS* mutation as a predictive marker for response to *EGFR* inhibition ([@bib25]; [@bib18]). In colorectal- and non-small-cell lung cancers, *KRAS* mutations have been reported to be associated with poor prognosis ([@bib29]; [@bib35]; [@bib10]). Mutation of *KRAS* has also been linked to polypoid growth in colorectal cancer ([@bib2]).

In endometrial cancer, it is mainly *KRAS* mutations that previously have been studied in relation to clinical phenotype ([@bib22]; [@bib12]; [@bib7]; [@bib14]; [@bib33]). Several studies have shown that *KRAS* mutations may be present in endometrial hyperplasia\'s with atypia, presumed to be precursor lesions, suggesting mutations as an early event in the endometrial carcinogenesis ([@bib23]). The prognostic importance of *KRAS* mutational status in endometrial carcinomas has been inconsistent. Two studies reported a 14% mutation rate with no prognostic impact ([@bib7]; [@bib33]), apparently in line with our data. In contrast, [@bib12] showed that 18% of 221 studied endometrial cancer patients had *KRAS* mutations associated with lymph-node metastasis and poor survival among patients above 60 years of age ([@bib12]). Their reported mutation rate is in line with our findings, but our higher frequency amongst endometrioid grade 1 and 2 tumours, and the same frequency of mutations detected in primary and metastatic lesions in the present study is in contrast to their findings but more in line with earlier studies linking *KRAS* mutations to early steps in endometrial carcinogenesis ([@bib26]).

Interestingly, in the present and to date most comprehensive study of *KRAS* alterations in primary and metastatic lesions from endometrial carcinoma patients, we find that high *KRAS* mRNA expression and *KRAS* amplification, in contrast to *KRAS* mutation, are associated with a large range of surrogate markers for unfavourable outcome and poor disease-specific survival. Apparently in line with this, we find a trend towards lower *KRAS* mRNA expression among *KRAS-*mutated cases, while samples with *KRAS* amplifications have significantly higher levels of *KRAS* mRNA expression and aggressive phenotype. Also the fact that mRNA expression levels and *KRAS* amplification increased significantly from primary- to metastatic lesions suggests an importance of theses alterations later in the carcinogenic process compared with *KRAS* mutations.

Of the differentially expressed genes in patients harbouring *KRAS* amplifications it is interesting that upregulation of Ets2 has been associated with poor prognosis in both pancreatic and breast cancer ([@bib40]; [@bib20]), and downregulation of SOX11 have been associated with poor prognosis in ovarian cancer ([@bib34]). However, more research needs to be done to elucidate *KRAS*-dependent gene expression regulation in endometrial cancer, which eventually could lead to new *KRAS-*targeted therapies.

To date, comprehensive genetic profiling of primary lesions searching for potential targets for new therapeutics, have led to only a few biomarker restricted clinical trials, of which some with promising results ([@bib13]). Still, in a setting with systemic disease, molecular alterations in metastatic lesions may be even more important, although so far basically unexplored for *KRAS* status in endometrial cancers. Our findings support that *KRAS* amplification and overexpression are more prevalent in metastatic compared with primary lesions, and may be of particular relevance for targeting therapies in a metastatic setting.

Our data clearly suggest that *KRAS* alterations are linked to clinical phenotypes in endometrial carcinomas with increase in copy-number and mRNA expression levels from primary to metastatic lesions.
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![Fluorescence *in situ* hybridisation (FISH) for *KRAS* copy numbers showing no *KRAS* amplification with CEP12 (green)/*KRAS* probe (red) ratio 2:2 (**A**); *KRAS* gain with *KRAS*/CEP12 gene probe ratio 2:3 (**B**); *KRAS* amplification with *KRAS*/CEP12 gene probe ratio 2:4 (**C**); *KRAS* polysomy with *KRAS*/CEP12 ratio 4:6 (**D**) and impact of copy numbers on disease-specific survival in endometrial carcinoma (**E**). Survival curves are estimated by the Kaplan--Meier method with numbers of cases (events) given for cases with amplification/gain compared with unamplified cases. Proportion of cases with *KRAS* gene amplification/gain increased significantly from primary (13 of 414) to metastatic (11 of 61) lesions (*P*\<0.001, FE test) (**F**).](bjc2012477f1){#fig1}

![Box-plots showing *KRAS* mRNA expression levels in relation to histological grade (**A**), endometrioid (**E**) and non-endometrioid (NE) histological subtypes (**B**), primary tumours (PT) *vs* metastatic lesions (ML) (**C**) and *KRAS* amplified *vs* unamplified status (SNP array ([@bib30])) (**D**). Estimated disease-specific survival according to expression levels of *KRAS* mRNA (qPCR) according to upper quartile with number of cases (events) given for each category.](bjc2012477f2){#fig2}

![Estimated disease-specific survival according to *KRAS* mutation status in endometrial carcinoma primary tumours with numbers of cases (events) for each category (**A**). Box-plots showing *KRAS* mRNA expression levels by qPCR in relation to *KRAS* mutation status (Mann--Whitney *U*-test) (**B**).](bjc2012477f3){#fig3}

###### Clinico-pathological variables related to *KRAS* gene amplification analysed by FISH for 414 patients

  **Variable**                              **Amplified,** ***n*** **(%)**   **Not amplified,** ***n*** **(%)**   ***P*****-value**[a](#t1-fn3){ref-type="fn"}
  ----------------------------------------- -------------------------------- ------------------------------------ ----------------------------------------------
  *Age*                                                                                                           
   ⩽66                                      3 (1.3)                          235 (98.7)                           0.01
   \>66                                     10 (5.7)                         166 (94.3)                            
                                                                                                                  
  *BMI*^b^                                                                                                        
   ⩽25                                      3 (2.2)                          135 (97.8)                           0.2
   \>25                                     10 (4.5)                         212 (95.5)                            
                                                                                                                  
  *FIGO stage*[c](#t1-fn4){ref-type="fn"}                                                                         
   I--II                                    7 (2.0)                          341 (98)                             0.009
   III--IV                                  6 (9.1)                          60 (90.9)                             
                                                                                                                  
  *Histological type*^d^                                                                                          
   Endometroid                              6 (1.8)                          335 (98.2)                           0.003
   Non-endometroid                          7 (9.6)                          66 (90.4)                             
                                                                                                                  
  *Grade*^e^                                                                                                      
   Low-medium                               3 (1.1)                          281 (98.9)                           0.002
   High                                     10 (7.9)                         117 (92.1)                            
                                                                                                                  
  *Lymph node*^f^                                                                                                 
   Negative                                 5 (1.7)                          298 (98.3)                           0.001
   Postitive                                5 (13.5)                         32 (86.5)                             
                                                                                                                  
  *Ploidy*^g^                                                                                                     
   Diploid                                  4 (1.7)                          231 (98.3)                           0.006
   Aneuploid                                5 (9.6)                          47 (90.4)                             
                                                                                                                  
  *ERα*^h^                                                                                                        
   Positive                                 5 (1.6)                          306 (98.4)                           0.003
   Negative                                 8 (8.4)                          87 (91.6)                             
                                                                                                                  
  *PR*^i^                                                                                                         
   Positive                                 3 (1)                            301 (99)                             \<0.001
   Negative                                 9 (8.6)                          96 (91.4)                             
                                                                                                                  
  *PIK3CA mut*^j^                                                                                                 
   N.m.d                                    7 (3.8)                          177 (96.2)                           0.33
   Mutated                                  0 (0)                            31 (100)                              
                                                                                                                  
  *P53*^k^                                                                                                        
   High                                     9 (100)                          0 (0)                                \<0.001
   Low                                      71 (21.9)                        253 (78.1)                            

Abbreviations: BMI=body mass index; ER=oestrogen receptor; FIGO=International Federation of Gynaecology and Obstetrics; FISH=fluorescence *in situ* hybridisation; KRAS=*Homo sapiens* v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d=no mutations detected; PR=progesterone receptor.

Data missing: ^b^54, ^d^8, ^e^3, ^f^74, ^g^127, ^h^4, ^i^7, ^j^199, ^k^81.

Fisher\'s exact test.

FIGO 2009 Criteria.

###### Clinico-pathological variables related to *KRAS* gene expression analysed by qPCR for 161 patients

  **Variable**                              **High expression,** ***n*** **(%)**   **Low expression,** ***n*** **(%)**    ***P*****-value**
  ----------------------------------------- -------------------------------------- ------------------------------------- -------------------
  *Age*                                                                                                                  
   ⩽66                                      20 (21.5)                              74 (78.5)                                     0.2
   \>66                                     21 (31.3)                              46 (68.7)                                       
                                                                                                                         
  *BMI*^a^                                                                                                               
   ⩽25                                      14 (25.5)                              41 (74.5)                                     0.7
   \>25                                     27 (28.1)                              69 (71.9)                                       
                                                                                                                         
  *FIGO stage*[b](#t2-fn4){ref-type="fn"}                                                                                
   I--II                                    28 (21.9)                              100 (78.1)                                   0.04
   III--IV                                  13 (39.4)                              20 (60.6)                                       
                                                                                                                         
  *Histological type*                                                                                                    
   Endometroid                              25 (18.9)                              107 (81.1)                                  \<0.001
   Non-endometroid                          16 (55.2)                              13 (44.8)                                       
                                                                                                                         
  *Grade*^c^                                                                                                             
   Low-medium                               17 (16)                                89 (84)                                     \<0.001
   High                                     24 (44.4)                              30 (55.6)                                       
                                                                                                                         
  *Lymph node*^d^                                                                                                        
   Negative                                 28 (22.2)                              98 (78.8)                                    0.02
   Positive                                 10 (52.6)                              9 (47.4)                                        
                                                                                                                         
  *Ploidy*^e^                                                                                                            
   Diploid                                  19 (19)                                80 (81)                                      0.001
   Aneuploid                                18 (50)                                18 (50)                                         
                                                                                                                         
  *ERα*^f^                                                                                                               
   Positive                                 21 (17)                                101 (83)                                    \<0.001
   Negative                                 19 (53)                                17 (47)                                         
                                                                                                                         
  *PR*^g^                                                                                                                
   Positive                                 20 (16)                                104 (84)                                    \<0.001
   Negative                                 19 (56)                                15 (44)                                         
                                                                                                                         
  *PIK3CA mut*^h^                                                                                                        
   N.m.d                                    33 (25.6)                              96 (74.4)                                    0.47
   Mutated                                  6 (28.6)                               15 (78.4)                                       
                                                                                                                         
  *P53*^i^                                                                                                               
   High                                     20 (57.1)                              15 (42.9)                                   \<0.001
   Low                                      17 (16.5)                              86 (83.5)                                       

Abbreviations: BMI=body mass index; ER=oestrogen receptor; FIGO=International Federation of Gynaecology and Obstetrics; KRAS=*Homo sapiens* v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d=no mutations detected; PR=progesterone receptor.

The *P*-value was based on the *χ*^2^-test or Fisher\'s exact test as indicated.

Data missing: ^a^10, ^c^1, ^d^16, ^e^26, ^f^3, ^g^3, ^h^11, ^i^23.

FIGO 2009 criteria.

###### Clinico-pathological variables correlated to status for *KRAS* mutation for 264 patients (Sanger sequencing)

  **Variable**                       ***KRAS*****mutated,** ***n*** **(%)**   ***KRAS*** **wt,** ***n*** **(%)**    ***P*****-value**[a](#t3-fn3){ref-type="fn"}
  ---------------------------------- ---------------------------------------- ------------------------------------ ----------------------------------------------
  *Age*                                                                                                            
   ⩽66                               23 (16.1)                                120 (83.9)                                                0.3
   \>66                              16 (13.2)                                105 (86.8)                                                  
                                                                                                                   
  *BMI*[b](#t3-fn4){ref-type="fn"}                                                                                 
   ⩽25                               8 (9.8)                                  74 (90.2)                                                 0.02
   \>25                              29 (20.7)                                111 (79.3)                                                  
                                                                                                                   
  *FIGO stage*^c^                                                                                                  
   I--II                             30 (13.6)                                185 (86.4)                                                0.4
   III--IV                           9 (18.4)                                 40 (81.6)                                                   
                                                                                                                   
  *Histological type*                                                                                              
   Endometroid                       37 (17.1)                                179 (82.9)                                                0.01
   Non-endometroid                   2 (4.2)                                  46 (95.8)                                                   
                                                                                                                   
  *Grade*^d^                                                                                                       
   Low-medium                        31 (18.5)                                137 (81.9)                                               0.003
   High                              8 (7.5)                                  86 (92.5)                                                   
                                                                                                                   
  *Lymph node*^e^                                                                                                  
   Negative                          27 (14.4)                                161 (85.6)                                                0.45
   Positive                          6 (21.4)                                 22 (78.6)                                                   
                                                                                                                   
  *Ploidy*^f^                                                                                                      
   Diploid                           25 (14.8)                                144 (85.2)                                                0.5
   Aneuploid                         7 (13.5)                                 45 (86.5)                                                   
                                                                                                                   
  *ERα*^g^                                                                                                         
   Positive                          28 (15.5)                                153 (84.5)                                                0.4
   Negative                          10 (17.5)                                47 (82.5)                                                   
                                                                                                                   
  *PR*^h^                                                                                                          
   Positive                          30 (16.9)                                148 (83.1)                                                0.3
   Negative                          8 (15.8)                                 55 (87.3)                                                   
                                                                                                                   
  *PIK3CA mut*^i^                                                                                                  
   N.m.d                             31 (14.6)                                181 (85.4)                                                0.2
   Mutated                           3 (8.3)                                  33 (91.7)                                                   
                                                                                                                   
  *P53*^j^                                                                                                         
   High                              7 (12.7)                                 48 (87.3)                                                 0.3
   Low                               26 (17.3)                                124 (82.7)                                                  

Abbreviations: BMI=body mass index; ER=oestrogen receptor; FIGO=International Federation of Gynaecology and Obstetrics; KRAS=*Homo sapiens* v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d=no mutations detected; PR=progesterone receptor.

Data missing: ^c^42, ^d^2, ^e^48, ^f^25, ^g^26, ^h^23, ^i^16, ^j^59.

*χ*^2^-test.

FIGO 2009 criteria.

###### Genes significantly differentially expressed in patients with amplified KRAS compared with non-amplified patients (FDR ⩽0.05)

  **Gene name**                **Description**                                         **Fold change**
  ---------------------------- ------------------------------------------------------- -----------------
  *Upregulated \>1.5 fold*                                                             
   *C6orf117*                  Chromosome 6 open reading frame 117                     3.3
   *ETS2*                      V-ets erythroblastosis virus E26 oncogene homologue 2   2.2
                                                                                       
  *Downregulated \>1.5 fold*                                                           
  * LMO1*                      LIM domain only 1                                       −3.8
  * CRTAC1*                    Cartilage acidic protein 1                              −2.5
  * SOX11*                     (Sex determining region Y)-box 11                       −1.8
  * UGT2A3*                    UDP glucuronosyltransferase 2 family, polypeptide A3    −1.6
  * FABP1*                     Fatty acid-binding protein 1                            −1.5
